GAIN THERAPEUTICS, INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
GAIN THERAPEUTICS, INC (GANX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 66.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-03-27
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 77.00%.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 66.00%, a 14.29% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 77.00%, a 3.75% decline from fiscal 2022.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 80.00%, a 0.00% change from fiscal 2021.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 80.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2024-12-31 | 66.00% 10-K · filed 2025-03-27 | |||
| 2023-12-31 | 77.00% 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 77.00% 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 77.00% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 77.00% 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | 80.00% 10-K · filed 2024-03-26 | |||
| 2022-09-30 | 80.00% 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 80.00% 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | 80.00% 10-K · filed 2023-03-23 | |||
| 2021-09-30 | 80.00% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 80.00% 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |